| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | Executive VP &President, Mrl
2 companies
Li Dean Y serves as a Director at RXRX and has filed Form 4s across 2 companies. Across recent SEC filings that breaks down to 0 buys and 9 sells. Those positions are worth an estimated $10.4M at current prices.
Historically, Li Dean Y's trades have earned a strong insider score of 73/100 across 5 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +44.7%.
The biggest single holding is MRK (~$10.4M) as Executive VP &President, Mrl. The recent filings there lean toward selling, a net 40,024 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb 10, 2026 | MRK Merck & Co., Inc. | Executive VP &President, Mrl | Sell | 10,235 | $117.52 | $1,202,843.81 | -10.0% | -5.0% | - | |
| Feb 4, 2026 | MRK Merck & Co., Inc. | Executive VP &President, Mrl | Sale+OE | 15,087 | $118.77 | $1,791,824.15 | -12.9% | -4.4% | - | |
| Feb 9, 2024 | MRK Merck & Co., Inc. | Executive VP &President, Mrl | Sale+OE | 14,702 | $125.50 | $1,845,083.36 | -24.1% | +4.5% | -28.5% | |
| Jan 9, 2024 | RXRX Recursion Pharmaceuticals, Inc. | Director | Sell10b5-1 | 29,000 | $13.66 | $396,213.83 | -6.4% | -32.8% | -45.8% | |
| Dec 7, 2021 | RXRX Recursion Pharmaceuticals, Inc. | Director | Sell | 15,900 | $20.48 | $325,630.39 | -1.2% | -65.8% | -55.0% | |
| Nov 19, 2021 | RXRX Recursion Pharmaceuticals, Inc. | Director | Sell | 19,100 | $20.16 | $384,962.04 | -3.2% | -46.3% | -50.4% |